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This review of population-based epidemiologic studies was conducted to provide background information on the 
rates and distribution of psychiatric disorders in Africa in the context of calls to broaden diversity in psychiatric 
genetic studies. The lifetime prevalence of mood, anxiety, substance use, and psychotic disorders ranged from 3.3-
9.8%, 5.7-15.8%, 3.7-13.3%, and 1.0-4.4%, respectively, in 36 studies from 12 African countries. While the 
prevalence of mood and anxiety disorders appears lower than that observed in research outside the continent, we 
identified similar distributions by gender though not by age or urbanicity. This review reveals gaps in epidemiologic 
research on psychiatric disorders and opportunities to leverage existing epidemiologic and genetic research within 
Africa to advance our understanding of psychiatric disorders. Studies that are methodologically comparable, but 
diverse in geographic context are needed to advance psychiatric epidemiology and provide a foundation for 




Studying the epidemiology of psychiatric disorders in Africa should lead to a deeper understanding of the frequency, 
patterns, distributions, and risk factors in populations residing in Africa and facilitate global cross-population 
comparisons. While it is widely presumed that the prevalence of psychiatric disorders with high heritability is 
roughly constant across the globe, psychiatric disorders with low heritability likely interact more strongly with 
modifying social and environmental risk factors that may influence their incidence and prevalence across 
populations. The last few years have seen several calls to broaden the scope of ancestral and geographic diversity in 
large scale genetic studies.1,2 The Psychiatric Genomics Consortium (PGC), the largest international consortium to 
study the genetic architecture of eleven psychiatric disorders, was formed in 2007 to launch a global effort to obtain 
the necessary large sample sizes for genome-wide association studies (GWAS). Although by 2020, the PGC had 
published several landmark studies on the genetic architecture of major psychiatric disorders, they were 
predominantly conducted in populations of Asian or European ancestry and outside of Africa.3 Research on the 
genetics of schizophrenia and bipolar disorder led by African and international researchers in Africa has been 
recently emerging, but remains underrepresented relative to studies in western countries. 4,5 Examining populations 
of similar ancestry that are underrepresented in existing genetics studies may enable the exploration of the role of 
environment and culture to be separated from genetic factors that contribute to psychiatric disorders.  
 
The originators and participants who provided data for genetic studies noted that it was essential that diverse 
populations and geography become better represented.1 Seventy-one percent of the individuals had been recruited 
from the United States, the United Kingdom, and Iceland.1 The call for a broadening of diversity they noted would 
"improve the effectiveness of genomic medicine by expanding the scope of known human genomic variations and 
bolstering our understanding of disease etiology,"pg 589.1 These statements were beginning to reflect efforts to 
carry out gene discovery in Africa.  
 
Data on the epidemiology of psychiatric disorder has flourished since Freedman's introduction of the Epidemiologic 
Catchment Areas study in 1984 with the editorial "Psychiatric Epidemiology Counts".6 Similar to genetic studies, 
these landmark epidemiologic studies focused primarily, but not exclusively, on populations of European descent in 
European or North American countries. The extent to which the prevalence and distribution of psychiatric disorder 
is comparable to populations in other settings is largely unknown. These gaps do not exist for some non-psychiatric 
disorders in Africa. For example, there have been large population-based epidemiological studies that have been 
critical to understanding HIV, neurological disorders such as epilepsy, among others.7,8 Epidemiologic studies on 
disorders that differ in prevalence among African relative to non-African populations have advanced our 
understanding of the etiology of these high-burden disorders, which may serve as a model for furthering knowledge 
on the epidemiology of psychiatric disorder in Africa.7  It was within this context that this review of the 
epidemiology of psychiatric disorders in Africa was undertaken. We are ultimately interested in exploring whether 
syndrome constructs are similar globally, potential environmental factors that modify prevalence, and the 
delineation of genetic and environmental factors that contribute to risk across populations. 
 
This paper is a scoping review of population-based studies to identify sources of evidence and gaps in existing 
research on the epidemiology of psychiatric disorders in Africa.9 The objective is to obtain information on 
prevalence and distributions of psychiatric disorders using clinical criteria and methods similar to those used in 
ongoing genetic studies. To guide the current scoping review, we focused on the following research questions: ‘How 
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has the prevalence of psychiatric disorders in African countries been estimated across population-based studies?’ 
and ‘What is the nature, range, and extent of the literature on the epidemiology of psychiatric disorders in Africa?’ 
This review aimed to explore the prevalence of psychiatric disorder based on geography (i.e., studies conducted in 




Rationale for a scoping review 
We conducted a scoping review to identify key concepts, sources of evidence, and gaps in existing research on the 
epidemiology of psychiatric disorders in Africa. Scoping reviews are appropriate for assessments in areas where the 
range of existing literature on a particular topic is initially uncertain, as was the case with the topic of this review. 
Accordingly, we have followed Arksey and O’Malley’s (2005) methodological framework of conducting a scoping 
review that entails identifying the research question, developing search strategies, selecting studies, charting data, 
and collating, summarizing and reporting the results.10 
 
Search strategy and selection criteria 
 
We searched three electronic databases: PubMed, EMBASE, and Web of Science to retrieve relevant literature from 
1984 onwards. We chose 1984 as this was the year that the first epidemiologic studies using clinical criteria were 
published11 and, we were interested in diagnoses that had been used in current genetic studies globally. The search 
strategy included three sets of search terms: those that are (i) relevant to psychiatric disorders; (ii) terms for each 
country in Africa; and (iii) related to prevalence and population-based surveys. Search terms were grouped using 
Boolean “or” operators, and the queries were combined using “and” operators as described below.  
 
1. Prevalence and (‘general population’ or community or population or epidemiolog*)  
 
2. Africa or Sub-Saharan Africa or Algeria or Egypt or Libya or Morocco or Tunisia or Cameroon or Central 
African Republic or Chad or Congo or Democratic Republic of the Congo or Equatorial Guinea or Gabon 
or Burundi or Djibouti or Eritrea or Ethiopia or Kenya or Rwanda or Somalia or Sudan or South Sudan or 
Tanzania or Uganda or Angola or Botswana or Lesotho or Mozambique or Ivory Coast or Namibia or 
South Africa or Swaziland or Zambia or Zimbabwe or Benin or Burkina Faso or Cote D’ivoire or Gambia 
or Ghana or Guinea or Guinea-Bissau or Liberia or Mali or Malawi or Mauritania or Mauritius or Burundi 
or Eswatini or Madagascar or Niger or Nigeria or Senegal or Sierra Leone or Togo  
 
3. (psychiatric and disorder*) or (mental and disorder*) or depress* or anxiety or ‘post-traumatic stress’ or 
PTSD or panic or (eating and disorder*) or schizo* or psychosis or bipolar or (mood and disorder*) or 
((substance or alcohol or drug) and (disorder* or abuse or dependence)) or (personality and disorder*) or 
ADHD or (emotional and problem*) or (behavioral and problem*) 
 
4. Search range: 1984/01/01– 2020/08/18  
 
5. Language: English, French, Portuguese  
 
6. #1 and #2 and #3 and #4 and #5 
We aimed to identify studies that reported on the prevalence of psychiatric disorder in a sample that was expected to 
be representative of the characteristics of the general population within the setting where the study was conducted. 
We were interested in exploring the study designs used to estimate prevalence and therefore did not restrict the 
results by sampling method (e.g., probability samples). Publications were eligible if they were quantitative 
community- and population-based studies published from 1984 onward and reported prevalence estimates of one or 
more psychiatric disorders in the general population in an African country. Prevalence estimates were described as 
point (i.e., current) prevalence, period (i.e., past year) prevalence, or lifetime (i.e., ever) prevalence. Studies that 
assessed psychiatric disorders but did not report one of these three prevalence rates were excluded. We restricted the 
search to English, French, or Portuguese articles. We did not exclude any studies based on sample size. Given the 
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focus of this article to study the prevalence of psychiatric disorders in Africa (i.e., geographic context), we excluded 
studies reporting on the prevalence of psychiatric disorders in population of African ancestry outside of Africa.  
 
Reference lists of eligible studies were reviewed to identify additional studies. Titles and abstracts were screened 
using the inclusion criteria, after which full articles were retrieved. Studies with irrelevant titles (such as those that 
included non-African populations or African populations residing outside Africa) were excluded, as were 
commentaries, conference abstracts, editorials, intervention studies, and theoretical papers. We also excluded studies 
on specific subpopulations (e.g., participants with medical conditions, treated samples, pregnant women). Potentially 
relevant full-text studies were then evaluated against review eligibility criteria by two authors (TY and MCG), and 
any discrepancies were resolved by consensus, including review by the senior author (MMW).  
 
Figure 1 presents a Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping 




We extracted data on the last name of the first author, year of publication, study location, year of data collection, 
study sample, age range, sample size, the diagnostic instrument, and prevalence of psychiatric disorders. Where the 
same parent study data were used in more than one publication, we put the reports together and deemed the papers 




The search yielded 20,075 records, 9798 of which were duplicate articles. We screened 9512 titles followed by 1103 
abstracts, which resulted in 105 articles assessed for eligibility. Fifty-three full text articles were excluded due to 
recruiting samples that weren’t representative of the general population (n=33records), not describing which type of 
prevalence estimate the study was reporting (n=18 records), not a community population-based study (n=5 records). 
One was conference abstract. One study of geriatric depression in Tanzania was classified as awaiting classification 
because the full text was not available and thus could not be fully evaluated against our eligibility criteria 13. Forty-
seven articles representing 36 unique studies were included in this review (Figure 1 shows the flow diagram). 
Included studies were published between 1996-2020, with half published after 2008 (n=28 articles). 
 
Setting and population characteristics 
 
Thirty-six studies estimated the prevalence of one or more psychiatric disorders in the general population in twelve 
countries in north, east, west, and southern Africa (Table 1; Supplemental File 1). Twenty-four studies were 
conducted in five of these countries: South Africa (n=8; 22.2%),14-28 Ethiopia (n=5; 13.9%),29-37 Kenya (n=5; 
13.9%),38-42 Nigeria (n=3; 8.3%),18-20,43-46 and Uganda (n=3; 8.3%).47-49 Remaining studies were conducted in Benin 
(n=1; 2.8%),50 Burkina Faso (n=2 studies; 5.6%),51,52 Egypt (n=2; 5.6%),53,54 Ghana (n=1; 2.8%),26 Morocco (n=2; 
5.6%),55,56 Mozambique (n=2; 5.6%),57-59 and Rwanda (n=2; 5.6%).60,61 Studies were designed to be nationally 
representative (n=10 studies),15-17,21-23,25-27,52-55 representative of populations in rural regions (n=14 studies),28,29,33-
35,37-41,47-50,58-60 a peri-urban community (n=1 study),24 or a region that included a mix of rural, urban, and/or peri-
urban communities (n=11 studies).14,18-20,30-32,36,42-46,51,56,57,61 Twelve studies aimed to estimate the prevalence of 
psychiatric disorders among adults at least 18 years of age.14,17-20,25,27,36,37,43,44,46-48,50,52,53,60,61 Eighteen studies aimed 
to estimate the prevalence of psychiatric disorders among adolescents and adults usually defined as 15 years or 
older.15,16,21,23,24,29-35,38-40,51,54-57 Three studies focused on either young children41 or children and adolescents.42,49 Two 
studies were restricted to older adults.22,26,45 One study was restricted to female heads of household.58,59 Recruitment 
and study interviews were completed at participant’s homes in all studies with one exception. One study that 
focused on estimating the prevalence of substance use disorder avoided conducting study interviews within the 




Participants were sampled using multi-stage cluster probability sampling procedures (n=25 studies),14-23,25-28,30-32,36-
39,42,43,45,46,49,51,52,55-59,61 simple or systematic random samples of households or individuals (n=6 studies),24,40,41,47,48,60 
enrolling all eligible persons in the sampling frame (n=2 studies),29,33-35 selecting a random direction from the center 
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of the village and approaching all households in that direction to identify eligible participants (n=1 study),50 or using 
a non-probability sampling method (n=2 studies).53,54 Sample sizes ranged from 351 to 68,491 individuals,33,35,48 
with a median sample size of 1769 individuals. In total, included studies enrolled 232,015 persons. 
 
Assessment of psychiatric disorders 
 
Case definitions for psychiatric disorder were most commonly informed by DSM-IV criteria (n=16 studies)14,17-
20,24,25,27,35,41,43,45-47,49-51,55,56,60,61 followed by ICD-10 (n=6 studies),22,26,30-34,38,39,54 DSM-5,40,44,58,59 or a combination of 
ICD-10 and DSM-IV (n=1 study).29 Psychiatric disorders were measured using diagnostic interviews in 21 studies 
using the World Health Organization World Mental Health Composite International Diagnostic Interview (CIDI),17-
20,22,25-27,29-35,45,46,50,62 the Mini International Neuropsychiatric Interview (MINI),14,40,44,49,51-53,55,56,61,63 and the Clinical 
Interview Schedule-Revised (CIS-R).38,39,64 Five of these studies combined the use of a diagnostic interview with 
screening tools,30-32,38,43,44,49 which included the Patient Health Questionnaire (PHQ-9),65 the Generalized Anxiety 
Disorder-7 (GAD-7),66 the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C),67 the Self 
Reporting Questionnaire (SRQ-20),68 and the Strengths and Difficulties Questionnaire (SDQ).69 Thirteen studies 
used screening tools to estimate the point, period, or lifetime prevalence of probable cases of psychiatric disorder 
using the Hopkins Symptom Checklist in combination with a locally developed functional impairment 
measure;47,60,70,71 the Center for Epidemiologic Studies Depression Scale (CES-D);24,72 the Patient Health 
Questionnaire (PHQ-8);58 the SRQ (point prevalence);36 the Child Behavior Checklist (CBCL; point 
prevalence);41,42,73 the Youth Self Report (YSR; point prevalence);42,74 the AUDIT-C (point prevalence);43,44 the 
AUDIT (point and period prevalence);23,24,48,59,75 the CAGE questionnaire (lifetime prevalence);15,16,21,76 the Alcohol, 
Smoking, and Substance Involvement Screening Test (ASSIST; point prevalence);37,77 adapted Addiction Severity 
Index (lifetime prevalence);54,78 and the Life Events Checklist (LEC)79 in combination with the Harvard Trauma 
Questionnaire (HTQ).24,80 Other methods included having participants maintain a diary recording their past-week 
alcohol consumption and applying NIAAA cutoffs to determine past-year harmful alcohol use,26 and locally 
developed questions and vignettes as part of structured and semi-structured interviews to increase community-based 
case identification of lifetime psychosis and intellectual disability.57 Nine studies reported using measures that had 
been adequately validated in the study population or country.18-20,24,40,43,44,47,55-57,60,62  
 
The prevalence of psychiatric disorders in Africa 
 
Mood and anxiety disorders 
Twenty-two studies estimated the prevalence of one or more mood disorders. The point, period, and lifetime 
prevalence of any mood disorder ranged from 3·8-6·4%, 1·1-4·9%, and 3·3-9·8%, respectively.17-19,25,46,53 The point, 
period, and lifetime prevalence of major depressive disorder ranged from 2·0-33·2%, 1·1-7·1%, and 0·3-26·2%, 
respectively (Table 2; Figure 2).17,20,22,24,25,27,28,33,40,43,45-47,52,53,58,60 Studies restricted to older adults and those that 
used screening tools to ascertain cases tended to report higher prevalence estimates relative to studies with younger 
populations and those that used diagnostic interviews. The prevalence of depression was consistently higher among 
females than males (prevalence ratio: 1·1-2·2) and lowest in studies conducted in Nigeria. The point and lifetime 
prevalence of bipolar disorder ranged from 0·1-3·2% and 0·0-5·2%, respectively. Studies reporting the prevalence 
of bipolar disorder by gender produced inconsistent findings. The point and lifetime prevalence of bipolar disorder 
were 2- and 6-fold higher among females in Ethiopia’s capital city, respectively;31 whereas, in a study conducted in 
a rural setting in Ethiopia, the lifetime prevalence of bipolar disorder was twice as high among males relative to 
females.35 Other studies examined the prevalence of major depressive episodes,31,49-52,55,61 affective problems,41 
recurrent depressive episode,31,52 persistent mood disorder,31 and dysthymia.46,49,50,52,53 
 
Eighteen studies estimated the prevalence of anxiety and stress-related disorders. The period and lifetime prevalence 
of anxiety disorders ranged from 4.1-8.1% and 5.7-15.8%, respectively (Table 3). Twelve of these studies reported 
the point prevalence of generalized anxiety disorder,17,25,38,39,43,46,50,52,53,55,56,61 which ranged from 0·9-36·5% (Table 
3). The point prevalence of generalized anxiety disorder, often referred to as the presence of symptoms during the 
past six months, which is consistent with the DSM-IV definition of current generalized anxiety disorder. Only one 
study reported a point prevalence of generalized anxiety disorder greater than 10%, which the authors attribute to the 
high prevalence of violence and history of trauma in post-genocide Rwanda. Three studies reported the past-year 
and/or lifetime prevalence of generalized anxiety disorder and estimated that 0·0-1·4% of the target population met 
criteria for generalized anxiety disorder in the past year and 0·1-4.0% met criteria for generalized anxiety disorder in 
their lifetime. The prevalence of generalized anxiety disorder was consistently higher among females relative to 
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males. Among children, the estimated point prevalence of anxiety problems was 12.6%41. Other anxiety disorders 
included panic disorder,17,25,38,39,46,50,52,53,55,56 agoraphobia,17,25,38,39,46,52,53,55,56 social phobia,17,25,38,39,46,50,52,53,55,56 




Nine studies estimated the prevalence of psychotic disorders. Four studies examined psychosis or psychotic 
disorders/syndromes generally,40,52,53,57 three assessed schizophrenia,28,29,34 and one study assessed both 
schizophrenia and schizoaffective disorder(Table 4; Figure 2).32 The point prevalence of psychosis in a nationally 
representative study in Egypt was 0·19%. The lifetime prevalence of psychosis was assessed in three different 
settings and ranged from 1% in a rural setting in Kenya, 1·6% in an urban setting in Mozambique, to 4·4% in a rural 
region of Mozambique. Two studies assessed psychotic syndrome. One of these studies conducted in Burkina Faso 
reported that 1.7% of the sample experienced isolated psychotic syndrome while the prevalence of recurrent 
psychotic syndrome was 4.1%.52 In a separate study conducted in Benin, the point prevalence of psychotic syndrome 
was 9.3% and the lifetime prevalence of psychotic syndrome was 30.2%.50 Another study examined the presence of 
psychotic symptoms without applying a diagnostic algorithm and found that 8% of persons 16-65 years of age in a 
rural region of Kenya displayed at least one symptom of psychosis in the past year. Three of the four studies 
evaluating the prevalence of schizophrenia and/or schizoaffective disorder were conducted in Ethiopia. These 
studies found that 0·06-0·3% of the population currently met criteria for schizophrenia, whereas the lifetime 
prevalence ranged from 0·40% in the capital city to 0·47% in a rural region of Ethiopia. One study assessed the 
point prevalence of paranoid schizophrenia in a rural setting in South Africa, which was estimated to be 5%.28 The 
only study evaluating schizoaffective disorder found that the point and lifetime prevalence of schizoaffective 
disorder in Addis Ababa, Ethiopia was 0·4% and 0·5%, respectively. The prevalence of schizophrenia was 
comparable between males and females; however, males were 2·5-3·5 times as likely to meet current or lifetime 
criteria for schizoaffective disorder. 
 
Substance use disorders 
Nineteen studies estimated the prevalence of alcohol or other drug use problems and/or disorder. In samples that 
enrolled adolescents and adults, the past-year and lifetime prevalence of any substance use disorder (alcohol or other 
drugs) ranged from 0·8-5·8% and 3·7-13·4%, respectively (Table 5; Figure 2). The case definitions for alcohol-
related problems varied and included hazardous/harmful alcohol use,23,26,37,43,44,48,52,59 alcohol problems,15,16,21 or 
alcohol use disorder (abuse/dependence).14,17,24,25,44,46,48,50,52,53,55 The point, period, and lifetime prevalence of alcohol 
use disorder (abuse or dependence) ranged from 0·03-16·7%, 0·5-35·5%, and 1.2-14·0%, respectively. The point, 
period and lifetime prevalence of non-alcohol substance use disorder ranged from 0·13-5·8%, 0·2-1·5%, 1·0-4·5%, 
respectively.17-19,25,40,43,44,46,50,52-55 Among studies that assessed both alcohol use disorder and other drug use disorder, 
studies conducted in Benin, Burkina Faso, Nigeria, and South Africa found the prevalence of alcohol use disorder to 
be approximately 2-3 times as prevalent as drug use disorders. In contrast, studies conducted in Egypt and Morocco 
found that other drug use disorders were up to twice as prevalent as alcohol use disorders. The prevalence of alcohol 
use disorders was 1·8-5·9 times more common among males relative to females, with the exception of Morocco, 
where the prevalence of alcohol use disorders was 14·5 times as prevalent among males relative to females. The 
prevalence of drug use disorder was consistently higher among males relative to females. Notably, in Morocco, the 
point prevalence of drug use disorder was 25 times greater among men (10%) relative to women (0·4%).55 
 
Other psychiatric disorders 
Other psychiatric disorders assessed in included somatoform disorders/problems (point prevalence: 0.7-11.8%; 
lifetime prevalence: 3.1%),30,42,53 dissociative disorders (point prevalence: 0.4%; lifetime prevalence: 0.8%),30 
insomnia,52 internalizing problems (point prevalence; 19.3%),42 impulse control and externalizing disorders (point 
prevalence of oppositional problems: 2.3% or externalizing problems 10.2%; period prevalence of externalizing 
disorders: 0.1%; lifetime prevalence of impulse control disorder: 0.3%),18,19,41,42 attention or attention-deficit 
hyperactivity problems (point prevalence: 2.3-5.0%),41,42 antisocial personality disorder (lifetime prevalence: 
3.1%),40,50 eating disorders (lifetime prevalence: 1.7%),40,50 mental retardation (lifetime prevalence: 1.3-1.9%),57 
pervasive developmental problems (point prevalence: 5.3%),41 seizure disorders (lifetime prevalence: 1.6%),57 and 
suicide risk and behaviors (lifetime prevalence: 6.7-16%; point prevalence: 4.2% low risk – 0.6% high risk).40,52,61 






In this scoping review, we identified 36 studies estimating the prevalence of one or more psychiatric disorders in the 
general population in twelve African countries, half of which were published after 2008. Studies reported lifetime 
prevalence estimates for mood, anxiety, substance use, and psychotic disorders ranging from 3.3-9.8%, 5.7-15.8%, 
3.7-13.3%, and 1.0-4.4%, respectively. Epidemiologic studies of psychiatric disorder in Africa use comparable 
diagnostic interviews and screening tools as studies conducted outside of the continent. However, this scoping 
review revealed significant sources of methodological and clinical heterogeneity as well as gaps in research on 
certain populations, settings, and disorders. 
 
First, there are gaps in coverage of epidemiologic estimates across countries, populations, and disorders. Only 
twelve African countries were represented in this review, none of which were conducted in central Africa. More 
than half of the population-based psychiatric epidemiology surveys in Africa were conducted in only five countries - 
Ethiopia, Kenya, Nigeria, South Africa, and Uganda. The included studies most frequently assessed mood and/or 
alcohol use disorders. Few studies examined psychotic disorders.  
 
Second, studies estimating the point prevalence of psychiatric disorder, particularly mood, anxiety, and substance 
use disorders, displayed substantial methodological variation in measurement approaches. Most studies used a 
diagnostic interview or screening tool, similar to those commonly used in other world regions, to measure 
psychiatric disorder. Studies that used screening tools often reported higher rates of psychiatric disorder than studies 
that utilized diagnostic interviews. For example, studies that estimated the prevalence of alcohol-related problems 
reported higher estimates when using the AUDIT or CAGE relative to the CIDI and MINI. Compared to diagnostic 
interviews in other countries, previous meta-analyses of screening tools have similarly found that the estimated 
prevalence of psychiatric disorder is greater for studies using screening tools relative to diagnostic interviews81. 
Other sources of measurement error may be due to differential misclassification by cultural context. Previous 
analyses of CIDI diagnoses from countries in Africa (Nigeria, South Africa), New Zealand, and the United States 
suggest that these diagnostic interviews underestimate the prevalence of depression in African countries relative to 
western contexts due to differential item performance and relevance across countries.82 It is also possible that 
screening and diagnostic tools do not capture the symptoms or features of psychiatric disorder that present in 
specific cultural contexts. For example, observed variation in substance use disorder may be partially attributable to 
the application of tools that do not cover all types of substances or use local terms for different types of substances. 
Khat, a stimulant plant with amphetamine-like properties, is widely used and culturally accepted in many parts of 
East Africa, and has been associated with psychosis and psychotic symptoms.83 Most epidemiologic screening and 
diagnostic tools do not capture khat use and related problems, which may underestimate substance use disorder in 
regions where khat use is prevalent. Scales that have been adapted to assess khat use were not included in the studies 
we identified in this review.84 This suggests the need to broaden the scope of substances to include those relevant to 
local use. In general, accurate measurement and the training of experts in the development and adaptation of 
screening and diagnostic tools is one of the greatest challenges for conducting psychiatric epidemiologic studies in 
all parts of the world. Strengthening capacity in psychometrics and measurement adaptation is needed and can 
leverage the training and capacity that has been developed for other disorders, such as epilepsy and other 
neurological disorders.7 There is also a need to improve reporting of these estimates. For example, several studies 
and data points were excluded because the authors did not specify which type of prevalence they were reporting. 
 
Third, while this review identified consistencies in the epidemiology of DSM and ICD psychiatric diagnoses with 
previous studies from countries outside of Africa, it is likely that applying these diagnostic tools may have excluded 
culturally specific presentations of mental health problems, idioms of distress, or culture-bound syndromes.85 There 
is significant debate regarding the relevance of universal application of western psychiatric diagnoses without 
cultural formulation and considerations.86 The absence of culture-bound syndromes and limited representation of 
local measurement approaches may also reflect limitations in our review process. Notably, we restricted studies to 
those published in English, French, and Portuguese and did not search grey literature databases. The official 
languages in most African countries include Afroasiatic languages and Niger-Congo languages; thus, this review 
may have missed eligible studies published in these common languages. Potential measurement error resulting from 
lack of cross-cultural validity, different assessment approaches (diagnostic interviews vs. screening tools), and 
unique presentations of psychiatric disorders and culture-bound syndromes suggest observed differences in the 
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prevalence of psychiatric disorder may be due, in part, to methodological and measurement differences between 
studies. 
 
Results from this review revealed notable heterogeneity in prevalence estimates across studies, which may be due to 
the methodology, but also differences in population characteristics and risk factors related to cultural norms and 
behaviors, social determinants of health, genetic differences, and geographic or contextual differences. Most 
psychiatric disorders, including those with high heritability, displayed comparable or lower estimated prevalence in 
studies conducted in Africa relative to large epidemiologic studies conducted outside of Africa (see Figure 2).18,19,87-
95 For example, the range in lifetime prevalence of mood (3.3-9.8%) and anxiety (5.7-15.8%) disorders was lower 
than that reported in countries from other world regions including Colombia (mood: 14.6%; anxiety: 25.3%), France 
(mood: 21.0%; anxiety: 22.3%), Lebanon (mood: 12.6%; anxiety: 16.7%), and the United States (mood: 21.4%; 
anxiety: 31.0%), but similar to that observed in Japan (mood: 7.6%; anxiety: 6.9%).19,87-95 The lifetime prevalence 
estimates for bipolar disorder were consistent with estimates from countries outside of Africa. The lifetime 
prevalence of alcohol use disorder was comparable to other countries (Colombia: 9.4%; France: 7.1%; Japan: 7.3%; 
Lebanon: 1.6%; United States: 13.8%). The lifetime prevalence of substance use disorder (1-4.5%) was higher than 
that reported for Japan (0.2%) and Lebanon (0.4%), but lower than the lifetime prevalence of substance use disorder 
in the United States (8.5%). Comparison with these other studies must be interpreted with caution given substantial 
clinical and methodological heterogeneity and also the lack of meta-analytic summary estimates that preclude 
statistical comparison of these estimates across world regions.  
 
It is possible that observed differences in the prevalence of psychiatric disorder are due to genetic and environmental 
risk or protective factors but may also be explained by confounders, stigma, and different cultural perceptions of 
mental disorders that may prevent people from reporting psychiatric symptoms.  For example, Africa has the 
youngest population globally, which may partially explain the lower observed general population prevalence 
estimates. Within studies conducted in Africa, we also observed substantial heterogeneity by region. The prevalence 
of alcohol use disorder was consistently lowest in North African countries and highest in South Africa. With the 
exception of the South African studies, the prevalence of alcohol use disorder was similar to previous studies from 
low- and middle-income countries and lower than those reported from high-income countries.89,96 The prevalence of 
drug use disorder in Morocco and South Africa was higher than most other low- and middle-income countries, yet 
comparable to estimates from high-income countries.97 Regional differences in the prevalence of substance use 
disorders may reflect the differences in the types of substances consumed and cultural norms related to substance 
use.   
 
The relative prevalence of psychiatric disorders by demographic subgroups displayed some consistencies and 
deviations from patterns observed outside of Africa. Gender differences in the prevalence of psychiatric disorders in 
Africa were consistent with studies outside of Africa, whereby major depression and generalized anxiety disorders 
were more common among females, while substance use disorders were more prevalent among males.88,89,91,96,97 
With regard to age, we found that the prevalence of emotional and behavioral problems among children was 
comparable to what has been observed outside of Africa,42,98,99 yet studies restricted to older adults produced higher 
period and lifetime prevalence estimates for major depressive disorder. This differs from epidemiologic studies of 
depression in high-income settings where the force of morbidity and period prevalence is often highest in early and 
middle-adulthood.19,93,100 A study of psychosis in Mozambique found a higher prevalence in rural relative to urban 
settings, which is in contrast to research from the United States and Western European countries that have 
consistently found a higher prevalence of schizophrenia in urban as compared to rural settings.101-103 
 
To better understand the global epidemiology of psychiatric disorders and set the foundation for future genetic 
research, we need studies that are methodologically comparable, but diverse in population characteristics, culture, 
and context. Epidemiologic and population-based research is needed to investigate factors that explain the observed 
heterogeneity of psychiatric disorder in Africa may further our understanding of the epidemiology of psychiatric 
disorders by disentangling methodological explanations for these differences from meaningful risk and protective 
factors. Furthermore, strengthening the infrastructure and capacity for conducting psychiatric epidemiologic 
research in Africa will facilitate further understanding of the role of genetic and environmental factors while also 
building equitable partnerships and ownership of psychiatric genetic epidemiology research among scientists in 
Africa. There is a rich history of genetics and epidemiologic research on HIV/AIDS,104,105 malaria,106 chronic and 
infectious diseases107 in Africa, including one of the first large-scale genomic studies of HIV and tuberculosis co-
infection,108 which have significantly advanced the global knowledge of the etiology of these diseases. Future 
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research should now include efforts to understand and measure culture-bound syndromes, unique presentations of 
and measurement considerations for DSM and ICD psychiatric disorders, and relevant disorders that were not 
covered in this review (e.g., autism spectrum disorder, epilepsy). Similar to the advances made in other chronic and 
infectious disease epidemiology, further investment in research on psychiatric disorders in Africa has the potential to 
develop a better understanding of the epidemiology and genetics of psychiatric disorder and to ultimately inform 
contextually relevant policies and practices aimed at reducing the burden of mental disorder and improving public 




MW conceived of the ideas of this review and TL, PS, and MLW further developed the rationale. MCG, TY, and  
MW designed the methodology for the scoping review. TY led the searches and initial screening of the study 
articles. MCG screened all full-text articles, verified eligibility of included articles and drafted the scoping review 
methodology. Any discrepancies in assessing the eligibility of potential articles were reviewed by MW. MCG, TY, 
and MW drafted the manuscript. All study authors provided revisions, critical feedback on the manuscript, and 
approved the final version. 
 
Declaration of interest 
 
• Authors MCG, TY, TL, LCG, CNP, CLM, WF, TLS, MAS, and MLW declare no competing interests 
• PFS- Reports personal fees and other from RBNC Therapeutics, from null, outside the submitted work. 
• AM- Reports personal fees from Janssen, personal fees from Illumina, grants from The Sackler Trust, 
outside the submitted work 
• JW- Reports grants from Takeda Pharmaceuticals Ltd, outside the submitted work.  
• MMW- Reports research grants in the last three years from NIMH, Brain and Behavior Foundation, 
Templeton Foundation and the Sackler Foundation at Columbia, and book royalties from the Perseus Press, 
Oxford Press, and APA Publishing. MMW has also received royalties on the social adjustment scale from 




Figure Titles and Captions 
 
Figure 1. Flow diagram 
 
 
Figure 2. Range of prevalence estimates by disorder as compared to World Mental Health Survey Estimates 
 
Caption: Range of point, period, and lifetime prevalence estimates for studies conducted in Africa. The shapes 





1. Peterson RE, Kuchenbaecker K, Walters RK, et al. Genome-wide Association Studies in 
Ancestrally Diverse Populations: Opportunities, Methods, Pitfalls, and Recommendations. Cell 2019; 
179(3): 589-603. 
2. Hindorff LA, Bonham VL, Brody LC, et al. Prioritizing diversity in human genomics research. 
Nat Rev Genet 2018; 19(3): 175-85. 
3. Cross-Disorder Group of the Psychiatric Genomics C, Lee SH, Ripke S, et al. Genetic 
relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013; 
45(9): 984-94. 
4. Stevenson A, Akena D, Stroud RE, et al. Neuropsychiatric Genetics of African Populations-
Psychosis (NeuroGAP-Psychosis): a case-control study protocol and GWAS in Ethiopia, Kenya, South 
Africa and Uganda. BMJ Open 2019; 9(2): e025469. 
5. Gulsuner S, Stein DJ, Susser ES, et al. Genetics of schizophrenia in the South African Xhosa. 
Science 2020; 367(6477): 569-73. 
6. Freedman DX. Psychiatric epidemiology counts. Arch Gen Psychiatry 1984; 41(10): 931-3. 
7. Ba-Diop A, Marin B, Druet-Cabanac M, Ngoungou EB, Newton CR, Preux PM. Epidemiology, 
causes, and treatment of epilepsy in sub-Saharan Africa. Lancet Neurol 2014; 13(10): 1029-44. 
8. Fauci AS. HIV and AIDS: 20 years of science. Nat Med 2003; 9(7): 839-43. 
9. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or 
scoping review? Guidance for authors when choosing between a systematic or scoping review approach. 
BMC Med Res Methodol 2018; 18(1): 143. 
10. Arksey H, O’Malley L. Scoping studies: Towards a methodological framework. International 
Journal of Social Research Methodology 2005; 8(1): 19-32. 
11. Weissman MM. Big Data Begin in Psychiatry. JAMA Psychiatry 2020. 
12. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): 
Checklist and Explanation. Ann Intern Med 2018; 169(7): 467-73. 
13. Adams DJ, Ndanzi T, Rweyunga AP, et al. Depression and associated factors among geriatric 
population in Moshi district council, Northern Tanzania. Aging Ment Health 2020: 1-7. 
14. Andersson LMC, Twum-Antwi A, Staland-Nyman C, van Rooyen DR. Prevalence and 
socioeconomic characteristics of alcohol disorders among men and women in the Eastern Cape Province, 
South Africa. Health Soc Care Community 2018; 26(1): e143-e53. 
15. Department of Health, Medical Research Council. South Africa Demographic and Health Survey 
1998. Pretoria: Department of Health, 2003. 
16. Department of Health, Medical Research Council. South Africa Demographic and Health Survey 
2003. Pretoria: Department of Health, 2007. 
17. Herman AA, Stein DJ, Seedat S, Heeringa SG, Moomal H, Williams DR. The South African 
Stress and Health (SASH) study: 12-month and lifetime prevalence of common mental disorders. S Afr 
Med J 2009; 99(5 Pt 2): 339-44. 
18. Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: an update 
from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc 2009; 18(1): 23-33. 
19. Kessler RC, Angermeyer M, Anthony JC, et al. Lifetime prevalence and age-of-onset 
distributions of mental disorders in the World Health Organization's World Mental Health Survey 
Initiative. World Psychiatry 2007; 6(3): 168-76. 
20. Kessler RC, Sampson NA, Berglund P, et al. Anxious and non-anxious major depressive disorder 
in the World Health Organization World Mental Health Surveys. Epidemiol Psychiatr Sci 2015; 24(3): 
210-26. 
21. Parry CD, Plüddemann A, Steyn K, Bradshaw D, Norman R, Laubscher R. Alcohol use in South 
Africa: Findings from the first Demographic and Health Survey. Journal of Studies on Alcohol 1998; 
66(1): 91-7. 
 12 
22. Peltzer K, Phaswana-Mafuya N. Depression and associated factors in older adults in South 
Africa. Glob Health Action 2013; 6: 1-9. 
23. Peltzer K, Phaswana-Mafuya N, Njubo P. Alcohol use and problem drinking in South Africa: 
Findings from a national population-based survey. African Journal of Psychiatry 2011; 14(1): 30-7. 
24. Smit J, Myer L, Middelkoop K, et al. Mental health and sexual risk behaviours in a South African 
township: a community-based cross-sectional study. Public Health 2006; 120(6): 534-42. 
25. Stein DJ, Seedat S, Herman A, et al. Lifetime prevalence of psychiatric disorders in South Africa. 
Br J Psychiatry 2008; 192(2): 112-7. 
26. Thapa SB, Martinez P, Clausen T. Depression and its correlates in South Africa and Ghana 
among people aged 50 and above: Findings from the WHO Study on global AGEing and adult health. J 
Psychiatry 2014; 17(6). 
27. Tomlinson M, Grimsrud AT, Stein DJ, Williams DR, Myer L. The epidemiology of major 
depression in South Africa: results from the South African stress and health study. S Afr Med J 2009; 99(5 
Pt 2): 367-73. 
28. Rumble S, Swartz L, Parry C, Zwarenstein M. Prevalence of psychiatric morbidity in the adult 
population of a rural South African village. Psychol Med 1996; 26(5): 997-1007. 
29. Fekadu A, Shibre T, Alem A, et al. Bipolar disorder among an isolated island community in 
Ethiopia. J Affect Disord 2004; 80(1): 1-10. 
30. Kebede D, Alem A. Major mental disorders in Addis Ababa, Ethiopia. III. Neurotic and 
somatoform disorders. Acta Psychiatr Scand Suppl 1999; 397: 24-9. 
31. Kebede D, Alem A. Major mental disorders in Addis Ababa, Ethiopia. II. Affective disorders. 
Acta Psychiatr Scand Suppl 1999; 397: 18-23. 
32. Kebede D, Alem A. Major mental disorders in Addis Ababa, Ethiopia. I. Schizophrenia, 
schizoaffective and cognitive disorders. Acta Psychiatr Scand Suppl 1999; 397: 11-7. 
33. Kebede D, Alem A, Shibre T, Negash A, Deyassa N, Beyero T. Socio-demographic correlates of 
bipolar disorder in Butajira, rural Ethiopia. East Afr Med J 2005; 82(1): 34-9. 
34. Kebede D, Alem A, Shibre T, et al. Onset and clinical course of schizophrenia in Butajira-
Ethiopia--a community-based study. Soc Psychiatry Psychiatr Epidemiol 2003; 38(11): 625-31. 
35. Negash A, Alem A, Kebede D, Deyessa N, Shibre T, Kullgren G. Prevalence and clinical 
characteristics of bipolar I disorder in Butajira, Ethiopia: a community-based study. J Affect Disord 2005; 
87(2-3): 193-201. 
36. Hunduma G, Girma M, Digaffe T, Weldegebreal F, Tola A. Prevalence and determinants of 
common mental illness among adult residents of Harari Regional State, Eastern Ethiopia. Pan Afr Med J 
2017; 28: 262. 
37. Gedif T, Azale T, Nigusie A. Substance use and associated factors among Gumuz people in 
Benishangul-Gumuz regional state, Mandura woreda, Northwest Ethiopia. Subst Abuse Treat Prev Policy 
2019; 14(1): 36. 
38. Jenkins R, Njenga F, Okonji M, et al. Psychotic symptoms in Kenya--prevalence, risk factors, and 
relationship with common mental disorders. Int J Environ Res Public Health 2012; 9(5): 1748-56. 
39. Jenkins R, Othieno C, Ongeri L, et al. Common mental disorder in Nyanza province, Kenya in 
2013 and its associated risk factors--an assessment of change since 2004, using a repeat household survey 
in a demographic surveillance site. BMC Psychiatry 2015; 15: 309. 
40. Kwobah E, Epstein S, Mwangi A, Litzelman D, Atwoli L. PREVALENCE of psychiatric 
morbidity in a community sample in Western Kenya. BMC Psychiatry 2017; 17(1): 30. 
41. Kariuki SM, Abubakar A, Kombe M, et al. Burden, risk factors, and comorbidities of behavioural 
and emotional problems in Kenyan children: a population-based study. Lancet Psychiatry 2017; 4(2): 
136-45. 
42. Magai DN, Malik JA, Koot HM. Emotional and Behavioral Problems in Children and 
Adolescents in Central Kenya. Child Psychiatry Hum Dev 2018; 49(4): 659-71. 
 13 
43. Adewuya AO, Atilola O, Ola BA, et al. Current prevalence, comorbidity and associated factors 
for symptoms of depression and generalised anxiety in the Lagos State Mental Health Survey (LSMHS), 
Nigeria. Compr Psychiatry 2018; 81: 60-5. 
44. Adewuya AO, Ola BA, Coker OA, et al. Descriptive epidemiology of alcohol use in the Lagos 
State Mental Health Survey (LSMHS), Nigeria. International Journal of Mental Health and Addiction 
2020: 1-12. 
45. Gureje O, Kola L, Afolabi E. Epidemiology of major depressive disorder in elderly Nigerians in 
the Ibadan Study of Ageing: a community-based survey. Lancet 2007; 370(9591): 957-64. 
46. Gureje O, Lasebikan VO, Kola L, Makanjuola VA. Lifetime and 12-month prevalence of mental 
disorders in the Nigerian Survey of Mental Health and Well-Being. Br J Psychiatry 2006; 188: 465-71. 
47. Bolton P, Wilk CM, Ndogoni L. Assessment of depression prevalence in rural Uganda using 
symptom and function criteria. Soc Psychiatry Psychiatr Epidemiol 2004; 39(6): 442-7. 
48. Nalwadda O, Rathod SD, Nakku J, Lund C, Prince M, Kigozi F. Alcohol use in a rural district in 
Uganda: Findings from community-based and facility-based cross-sectional studies. International Journal 
of Mental Health Systems 2018; 12(1): 12. 
49. Kinyanda E, Kizza R, Abbo C, Ndyanabangi S, Levin J. Prevalence and risk factors of depression 
in childhood and adolescence as seen in four districts of North-Eastern Uganda. BMC Int Health Hum 
Rights 2013; 13: 19. 
50. Tognon-Tchégnonsi F, Adoukonou T, Djidonou A, Ataigba Ireti E, Gandaho P. Prévalence des 
troubles mentaux dans une communauté rurale a 
Parakou au nord Bénin. Annales Médico-Psychologiques 2020; 178: 908-12. 
51. Duthe G, Rossier C, Bonnet D, Soura AB, Corker J. Mental health and urban living in sub-
Saharan Africa: major depressive episodes among the urban poor in Ouagadougou, Burkina Faso. Popul 
Health Metr 2016; 14: 18. 
52. Ouedraogo A, Ouango JG, Karfo K, Goumbri P, Nanema D, Sawadogo B. [Prevalence of mental 
disorders in the general population of Burkina Faso]. Encephale 2019; 45(4): 367-70. 
53. Ghanem M, Gadallah M, Meky FA, Mourad S, El-Kholy G. National Survey of Prevalence of 
Mental Disorders in Egypt: preliminary survey. East Mediterr Health J 2009; 15(1): 65-75. 
54. Hamdi E, Gawad T, Khoweiled A, et al. Lifetime prevalence of alcohol and substance use in 
Egypt: a community survey. Subst Abus 2013; 34(2): 97-104. 
55. Kadri N, Agoub M, Assouab F, et al. Moroccan national study on prevalence of mental disorders: 
a community-based epidemiological study. Acta Psychiatr Scand 2010; 121(1): 71-4. 
56. Kadri N, Agoub M, El Gnaoui S, Berrada S, Moussaoui D. Prevalence of anxiety disorders: a 
population-based epidemiological study in metropolitan area of Casablanca, Morocco. Ann Gen 
Psychiatry 2007; 6: 6. 
57. Patel V, Simbine AP, Soares IC, Weiss HA, Wheeler E. Prevalence of severe mental and 
neurological disorders in Mozambique: a population-based survey. Lancet 2007; 370(9592): 1055-60. 
58. Audet CM, Wainberg ML, Oquendo MA, et al. Depression among female heads-of-household in 
rural Mozambique: A cross-sectional population-based survey. J Affect Disord 2018; 227: 48-55. 
59. Wainberg M, Oquendo MA, Peratikos MB, et al. Hazardous alcohol use among female heads-of-
household in rural Mozambique. Alcohol 2018; 73: 37-44. 
60. Bolton P, Neugebauer R, Ndogoni L. Prevalence of depression in rural Rwanda based on 
symptom and functional criteria. J Nerv Ment Dis 2002; 190(9): 631-7. 
61. Umubyeyi A, Mogren I, Ntaganira J, Krantz G. Intimate partner violence and its contribution to 
mental disorders in men and women in the post genocide Rwanda: findings from a population based 
study. BMC Psychiatry 2014; 14: 315. 
62. Kessler RC, Abelson J, Demler O, et al. Clinical calibration of DSM-IV diagnoses in the World 
Mental Health (WMH) version of the World Health Organization (WHO) Composite International 
Diagnostic Interview (WMHCIDI). Int J Methods Psychiatr Res 2004; 13(2): 122-39. 
 14 
63. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview 
(M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV 
and ICD-10. J Clin Psychiatry 1998; 59 Suppl 20: 22-33;quiz 4-57. 
64. Lewis G, Pelosi AJ, Araya R, Dunn G. Measuring psychiatric disorder in the community: a 
standardized assessment for use by lay interviewers. Psychol Med 1992; 22(2): 465-86. 
65. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. 
J Gen Intern Med 2001; 16(9): 606-13. 
66. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety 
disorder: the GAD-7. Arch Intern Med 2006; 166(10): 1092-7. 
67. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption 
questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality 
Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998; 
158(16): 1789-95. 
68. World Health Organization. A user’s guide to the Self Reporting Questionnaire (SRQ). Geneva: 
Division of Mental Health, World Health Organization; 1994. p. 1-84. 
69. Goodman R. The Strengths and Difficulties Questionnaire: a research note. J Child Psychol 
Psychiatry 1997; 38(5): 581-6. 
70. Bolton P, Tang AM. An alternative approach to cross-cultural function assessment. Soc 
Psychiatry Psychiatr Epidemiol 2002; 37(11): 537-43. 
71. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist 
(HSCL): a self-report symptom inventory. Behav Sci 1974; 19(1): 1-15. 
72. Carleton RN, Thibodeau MA, Teale MJ, et al. The center for epidemiologic studies depression 
scale: a review with a theoretical and empirical examination of item content and factor structure. PLoS 
One 2013; 8(3): e58067. 
73. Achenbach TM, Edelbrock C, Howell CT. Empirically based assessment of the 
behavioral/emotional problems of 2- and 3- year-old children. J Abnorm Child Psychol 1987; 15(4): 629-
50. 
74. Achenbach TM. Manual for the youth self report and 1991 profile. Burlington: University of 
Vermont; 1991. 
75. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use 
Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with 
Harmful Alcohol Consumption--II. Addiction 1993; 88(6): 791-804. 
76. O'Brien CP. The CAGE questionnaire for detection of alcoholism: a remarkably useful but simple 
tool. JAMA 2008; 300(17): 2054-6. 
77. Humeniuk R, Ali R, Babor TF, et al. Validation of the Alcohol, Smoking And Substance 
Involvement Screening Test (ASSIST). Addiction 2008; 103(6): 1039-47. 
78. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. 
Journal of Substance Abuse Treatment 1992; 9(3): 199-213. 
79. Weathers FW, Litz BT, Keane TM, Palmieri PA, Marx BP, Schnurr PP. The PTSD Checklist for 
DSM-5 (PCL-5) - LEC-5 and Extended Criterion A. VA, 2013. 
80. Mollica RF, Caspi-Yavin Y, Bollini P, Truong T, Tor S, Lavelle J. The Harvard Trauma 
Questionnaire. Validating a cross-cultural instrument for measuring torture, trauma, and posttraumatic 
stress disorder in Indochinese refugees. J Nerv Ment Dis 1992; 180(2): 111-6. 
81. Levis B, Yan XW, He C, Sun Y, Benedetti A, Thombs BD. Comparison of depression prevalence 
estimates in meta-analyses based on screening tools and rating scales versus diagnostic interviews: a 
meta-research review. BMC Med 2019; 17(1): 65. 
82. Scorza P, Masyn K, Salomon JA, Betancourt TS. The impact of measurement differences on 
cross-country depression prevalence estimates: A latent transition analysis. PLoS One 2018; 13(6): 
e0198429. 
83. Lifson AR, Workneh S, Shenie T, et al. Prevalence and factors associated with use of khat: a 
survey of patients entering HIV treatment programs in Ethiopia. Addict Sci Clin Pract 2017; 12(1): 3. 
 15 
84. Odenwald M, Neuner F, Schauer M, et al. Khat use as risk factor for psychotic disorders: a cross-
sectional and case-control study in Somalia. BMC Med 2005; 3: 5. 
85. Kirmayer LJ, Jarvis GE. Depression across cultures. In: Stein DJ, Schatzberg AF, Kupfer D, eds. 
Textbook of Mood Disorders. Washington: American Psychiatric Press; 2005: 611-29. 
86. Alarcon RD. Culture, cultural factors and psychiatric diagnosis: review and projections. World 
Psychiatry 2009; 8(3): 131-9. 
87. Williams DR, Gonzalez HM, Neighbors H, et al. Prevalence and distribution of major depressive 
disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the National 
Survey of American Life. Arch Gen Psychiatry 2007; 64(3): 305-15. 
88. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R 
psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen 
Psychiatry 1994; 51(1): 8-19. 
89. Hasin DS, Grant BF. The National Epidemiologic Survey on Alcohol and Related Conditions 
(NESARC) Waves 1 and 2: review and summary of findings. Soc Psychiatry Psychiatr Epidemiol 2015; 
50(11): 1609-40. 
90. Appel HB, Huang B, Ai AL, Lin CJ. Physical, behavioral, and mental health issues in Asian 
American women: results from the National Latino Asian American Study. J Womens Health (Larchmt) 
2011; 20(11): 1703-11. 
91. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression 
and bipolar disorder. JAMA 1996; 276(4): 293-9. 
92. Robins LN, Helzer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders 
in three sites. Arch Gen Psychiatry 1984; 41(10): 949-58. 
93. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and 
age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch 
Gen Psychiatry 2005; 62(6): 593-602. 
94. Regier DA, Myers JK, Kramer M, et al. The NIMH Epidemiologic Catchment Area program. 
Historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984; 
41(10): 934-41. 
95. World Mental Health Survey Initiative. The World Mental Health Survey Initiative. 2005. 
https://www.hcp.med.harvard.edu/wmh/ (accessed December 11 2020). 
96. Glantz MD, Bharat C, Degenhardt L, et al. The epidemiology of alcohol use disorders cross-
nationally: Findings from the World Mental Health Surveys. Addict Behav 2020; 102: 106128. 
97. Degenhardt L, Bharat C, Glantz MD, et al. The epidemiology of drug use disorders cross-
nationally: Findings from the WHO's World Mental Health Surveys. Int J Drug Policy 2019; 71: 103-12. 
98. Philipp J, Zeiler M, Waldherr K, et al. Prevalence of emotional and behavioral problems and 
subthreshold psychiatric disorders in Austrian adolescents and the need for prevention. Soc Psychiatry 
Psychiatr Epidemiol 2018; 53(12): 1325-37. 
99. Yang Y, Qi Y, Cui Y, et al. Emotional and behavioral problems, social competence and risk 
factors in 6-16-year-old students in Beijing, China. PLoS One 2019; 14(10): e0223970. 
100. Eaton WW, Kalaydjian A, Scharfstein DO, Mezuk B, Ding Y. Prevalence and incidence of 
depressive disorder: the Baltimore ECA follow-up, 1981-2004. Acta Psychiatr Scand 2007; 116(3): 182-
8. 
101. Eaton WW. Residence, social class, and schizophrenia. J Health Soc Behav 1974; 15(4): 289-99. 
102. Lewis G, David A, Andreasson S, Allebeck P. Schizophrenia and city life. Lancet 1992; 
340(8812): 137-40. 
103. Eaton WW, Mortensen PB, Frydenberg M. Obstetric factors, urbanization and psychosis. 
Schizophr Res 2000; 43(2-3): 117-23. 
104. Kilmarx PH. Global epidemiology of HIV. Curr Opin HIV AIDS 2009; 4(4): 240-6. 
105. Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels the spread of 
both diseases in sub-Saharan Africa. Science 2006; 314(5805): 1603-6. 
 16 
106. Alilio MS, Bygbjerg IC, Breman JG. Are multilateral malaria research and control programs the 
most successful? Lessons from the past 100 years in Africa. Am J Trop Med Hyg 2004; 71(2 Suppl): 268-
78. 
107. Tekola-Ayele F, Adeyemo AA, Rotimi CN. Genetic epidemiology of type 2 diabetes and 
cardiovascular diseases in Africa. Prog Cardiovasc Dis 2013; 56(3): 251-60. 
108. Mboowa G, Mwesigwa S, Katagirya E, et al. The Collaborative African Genomics Network 
(CAfGEN): Applying Genomic technologies to probe host factors important to the progression of HIV 












Table 1. Characteristics of included studies 
First author, year Country, DC 
year 
Sample  Age Diagnostic interview 
[Sample size]  
1a. Adewuya et al. (2018) Nigeria 
2015 
Multistage sampling; Representative 
of Lagos state (urban/peri-urban); 







1b. Adewuya et al. (2020) DSM-5 
MINI-5.0 
[n =11246] 
2. Andersson et al. (2018) South Africa 
2012 
Multistage sampling; Representative 
of the Eastern Cape Province 
(urban/peri-urban) 
18-40 DSM-IV MINI 
[n = 977] 
3a. Audet et al. (2018) Mozambique 
2014 
Multistage sampling; Representative 
of female heads of household in 14 





[n = 3892] 3b. Wainberg et al. (2018) 
4. Bolton et al. (2002) Rwanda 1999 Random sample of households; 




[n = 368] 
5. Bolton et al. (2004) Uganda 2000 
 
Systematic random sample of 
households; Representative of Masaka 




[n = 587] 
6. Department of Health, 




Multistage sampling; Representative 
of South Africa (national); South 
Africa Demographic and Health 
Survey 2003 
15+ CAGE Questionnaire 
[n = 10214] 
7. Duthe et al. (2016) Burkina Faso 
2010 
Multistage sampling; Representative 
of Ouagadougou (peri-urban); 
Ouagadougou Health and 









[n = 1691] 
9. Gedif et al. (2019) Ethiopia 2018 Multistage sampling; Representative 
of Mandura Woreda (rural) 
18+ ASSIST 
[n=1588] 
10. Ghanem et al. (2009) Egypt 
2003 
Purposive sampling of sites selected 
to represent different socioeconomic, 
cultural, and geographic 
characteristics in Egypt (national) 
8-64 MINI-Plus 
[n = 14640] 
11. Gureje et al. (2007) Nigeria 
2003-2004 
 
Multistage sampling; Representative 
or Yoruba-speaking areas of Nigeria 
(urban/peri-urban/rural); Ibadan Study 
of Aging  
65+ DSM-IV 
CIDI 
[n = 2152] 
12a. Gureje et al. (2006) Nigeria 
2001-2003 
 
Multi-stage sampling; Representative 
or Yoruba-speaking areas of Nigeria 
(urban/peri-urban/rural); Nigerian 
Survey of Mental Health and Well-
Being  
18+ DSM-IV CIDI 
[n = 4985] 
 
12b. Kessler et al. (2015, 2009, 
2007) 
[n = 2143] 
[n = 6752] 
18-39 [n = 1203] 
13. Hamdi et al. (2013) Egypt 
2005-2006 
Purposive stratified sampling of 




[n = 44000] 
14a. Herman et al. (2009) South Africa 
2002-2004 
Multistage sampling; Representative 
of South Africa (national); South 




[n = 4351] 




[n = 4315] 
14c. Stein et al. (2008) DSM-IV 
CIDI 3.0 
[n = 4433] 
14d.Tomlinson et al. (2009) DSM-IV 
CIDI 3.0 
[n = 4351] 
15. Hunduma et al. (2017) Ethiopia 2016 Multistage sampling; Representative 




16. Jenkins et al. (2012) Kenya  
2000 
Multistage sampling; Representative 





[n = 876] 
17.  Jenkins et al. (2015) Kenya 
2004-2013 
Multistage sampling; Representative 




[n = 1158] 
18. Kadri et al. (2007) Morocco 1994 
 
Multistage sampling; Representative 




[n = 800] 
19. Kadri et al. (2010) Morocco 
2004-2005 
Multistage sampling; Representative 
of Morocco (national) 
15+ DSM-IV 
MINI 
[n = 5498] 
20. Kariuki et al. (2017) Kenya Simple random sample of parent-
children dyads; Representative of 
Kilifi county (rural); Kilifi Health and 




21a. Kebede et al. (1999a) 
 
21b.  Kebede et al. (1999b) 
 
21c.  Kebede et al. (1999c) 
Ethiopia 
1994 
Multistage sampling; Representative 




[n = 1420] 





22b. Kebede et al. (2005)  
Ethiopia 
1998-2001 
Complete coverage of Butajira, 




[n = 68378] 
 
 
[n = 68491] 
22c. Negash et al. (2005) DSM-IV/ 
CIDI 
SCAN 
[n = 68378] 
23. Kinyanda et al. (2013) Uganda Multistage sampling; Representative 
of Lira, Tororo, Kaberamaido, and 









Random sample of individuals; 
Representative of Kosirai division, 
Nandi County (rural) 
15+ DSM-5 
MINI-7 
[n = 420] 
25. Magai et al. (2018) Kenya Multistage sampling; Representative 





26. Nalwadda et al. (2018) Uganda 
2013 
Random sample of households; 
Representative of Kamuli District 
(rural)  
18+ AUDIT 
[n = 351] 
27. Ouedraogo et al. (2019) Burkina Faso Multistage sampling; Representative 
of Burkina Faso (national) 
18+ MINI 
[n=2587] 
28. Parry et al. (1998) South Africa 
1998 
Multisage sampling; Representative of 
South Africa (national); First South 
African Demographic and Health 
Survey (SADHS)  
15+ CAGE Questionnaire 
[n = 13826] 
29. Patel et al. (2007) Mozambique 
2003 
Multistage sampling; Representative 
of Maputo City (urban) 
17+ SI & SSI 
[n = 1796] 
Mozambique 
2003 
Multistage sampling; Representative 
of Cuamba city (rural)  
17+ SI & SSI 
[n = 943] 
30. Peltzer et al. (2011) South Africa 
2008 
Multistage sampling; Representative 
of South Africa (national); South 
African National HIV Incidence, 
Behaviour & Communication 
(SABSSM) survey 
15+ AUDIT 
[n = 15828] 
31a. Peltzer et al. (2013) South Africa 
2007-2009 
Multistage sampling; Representative 
of South Africa; National population-
based study- Study of Global AGEing 
& Adult Health  
(SAGE) 
50+ ICD-10  
CIDI 
[n = 3840] 
31b. Thapa et al. (2014) NIAAA/ 
Diary recording alcohol 
use  
[n = 3668] 
32. Rumble et al. (1996) South Africa 
1992 
Multistage sampling; Representative 
of Mamre village (rural) 
15+ SRQ 
PSE-CATEGO  
[n = 560] 
33. Smit et al. (2006) South Africa 
2002 
Random sample of households; 
Representative of a township outside 





[n = 645] 
34. Thapa et al. (2014) Ghana 
2007-2009 
Multistage sampling; Representative 
of Ghana; National population-based 
study- Study of Global AGEing & 
Adult Health  
(SAGE) 
50+ NIAAA 
Diary recording alcohol 
use 
[n = 4289] 
35. Tognon-Techégnonsi et al. 
(2020) 
Benin 2013 Sampling of households along a 





36.Umubyeyi et al. (2014) Rwanda 
2011-2012 
Multistage sampling; Representative 
of eight districts in the Southern 
Province (primarily rural) 
20-35 DSM-IV 
MINI 5.0 
[n = 917] 
Abbreviations:  Alcohol Use Disorder; AUDIT = Alcohol Use Disorder Identification Test; ASI = Addiction Severity Index; 
CES-D = Center for Epidemiologic Study for Depression Scale; CIDI = Composite International Diagnostic Interview; CIS-R = 
Clinical Interview Schedule- Revised; DHSCL = Depression Section of the Hopkins Symptom Checklist; DSM= Diagnostic and 
Statistical Manual of Mental Disorders; ICD-10 = International Classification of Disease, 10th revision; LEC = Life Event 
 
Check-list; MINI = Mini-International Neuropsychiatric Interview; NIAAA = National Institute on Alcohol Abuse and 
Alcoholism; PHQ = Patient Health Questionnaire; PSQ = Psychosis Screening Questionnaire; SCAN = Schedule for Clinical 
Assessment in Neuropsychiatry; SI = Structured Interview; SQ = Structured Questionnaire; SRQ = Self-Reporting 
Questionnaire; SSI = Semi-structured Interview; WHODAS-II = World Health Organization Disability Assessment Schedule 
2.0  




          




Criteria Measure MD MDD DE DY BD 
Benin Tognon-Techégnonsi 2020 2013 603 18+ DSM-IV CIDI .. .. 32.3 .. .. 
Burkina Faso Duthe 2016 2010 2187 15+ DSM-IV MINI .. .. 4.3 .. .. 
Burkina Faso Ouedraogo 2019 .. 2587 18+ .. MINI .. 5.1 11.6 10.1 .. 
Egypt Ghanem 2009 2003 14640 18-64 .. MINI-Plus 6.4 2.7 .. 1.0 .. 
Ethiopia Fedaku 2004 1998 1691 16+ ICD-10 CIDI/ SCAN .. .. .. 
.. 1.8 
Ethiopia Kebede 1999b 1994 1420 15+ ICD-10 CIDI/SRQ 3.8 .. 2.1 .. 0.1 
Kenya Jenkins 2012 2000 876 16-65 ICD-10 CIS-R .. .. 0.7 .. .. 
Kenya Jenkins 2015 2004-2013 1158 16-65 ICD-10 CIS-R .. .. 0.9 
.. .. 
Morocco Kadri 2010 2004-2005 5498 15+ DSM-IV MINI .. 26.5 .. 
.. 3.2 
Mozambique Audet 2018 2014 3892 16-62 DSM-IV PHQ-8 .. 14.0 .. .. .. 
Nigeria Adewuya 2018 2015 11246 18-40 DSM-IV MINI-5, PHQ-9 .. 5.5 .. 
.. .. 
Rwanda Bolton 2002 1999 368 18+ DSM-IV DHSCL .. 15.5 .. .. .. 
Rwanda Umubyeyi 2014 2011-2012 917 20-35 DSM-IV MINI-5 .. .. 19.6 
.. .. 
South Africa Rumble 1996 1992 560 15+ .. SRQ PSE-CATEGO .. 2.0 .. 
.. .. 
South Africa Smit 2006 2002 645 15+ DSM-IV CES-D .. 33.2 .. .. .. 
Uganda Bolton 2004 2000 587 18+ DSM-IV DHSCL, WHODAS .. 21.0 .. 
.. .. 
Uganda Kinyanda 2013 .. 1587 3-19 DSM-IV MINI-KID .. .. 7.6 .. .. 
PERIOD 
PREVALENCE            




Criteria Measure MD MDD DE DY BD 
Benin Tognon-Techégnonsi 2020 2013 603 18+ DSM-IV CIDI .. .. 11.6 .. .. 
Nigeria Gureje 2007 2003-2004 2152 65+ DSM-IV CIDI .. 7.1 .. 
.. .. 




6752 18+ DSM-IV CIDI 
1.1-
1.3 1.1 .. 0.1 0.0 
South Africa 
Herman 2009; Kessler 
2007, 2009, 2015; Stein 
2008; Tomlinson 2009 
2002-
2004 4351 18+ DSM-IV CIDI 4.9 4.9 .. 
.. 
.. 
South Africa Peltzer 2013 2007-2009 3840 50+ ICD-10 CIDI .. 4.0 .. 
.. .. 
LIFETIME 
PREVALENCE            




Criteria Measure MD MDD DE DY BD 
Ethiopia Kebede 1999b 1994 1420 15+ ICD-10 CIDI/SRQ 5.0 .. .. .. 0.3 






15-49 ICD-10 & DSM-IV 
CIDI/SCA
N .. 0.3 .. 
.. 
0.5 
Kenya Kwobah 2017 2015-2016 420 15+ DSM-5 MINI .. 12.6 .. 
.. 5.2 
Nigeria Gureje 2007 2003-2004 2152 65+ DSM-IV CIDI .. 26.2 .. 
.. .. 




6752 18+ DSM-IV CIDI 
3.3-
4.1 3.1 .. 0.2 0.0 
South Africa 
Herman 2009; Kessler 
2007, 2009, 2015; Stein 
2008; Tomlinson 2009 
2002-
2004 4351 18+ DSM-IV CIDI 9.8 
9.7-
9.8 .. .. .. 
Disorder Abbreviations - BD: Bipolar Disorder, DE: Depressive Episode, DY: Dysthymia, MD: Mood Disorder, 
MDD: Major depressive disorder 
 
 




              









2013 603 18+ DSM-IV CIDI .. 9.6 3.5 .. 20.7 14.3 .. 11.1 
Burkina Faso Ouedraogo 
2019 .. 2587 18+ .. MINI .. 4.0 5.0 3.6 .. 2.7 .. 4.1 
Egypt Ghanem 
2009 2003 14640 18-64 .. 
MINI-
Plus 4.8 0.9 0.7 .. 0.7 0.2 1.4 0.11 
Kenya Jenkins 




2013 1158 16-65 ICD-10 CIS-R .. 0.7 3.1 .. 1.4 .. 0.4 .. 
Morocco Kadri 2007 1994 800 15-80 DSM-IV MINI .. 4.3 2.0 7.6 6.1 3.4 14.3 3.4 
 Kadri 2010 2004-
2005 5498 15+ DSM-IV MINI .. 9.3 6.6 9.4 6.6 6.3 .. 2.1 
Nigeria Adewuya 




2012 917 20-35 DSM-IV MINI-5 .. 36.5 .. .. .. .. .. 13.6 
South Africa Smit 2006 2002 645 15+ DSM-IV LEC, HTQ .. .. .. .. .. .. .. 14.9 
PERIOD 
PREVALENCE 
              











6752 18+ DSM-IV CIDI 4.1 0.0 0.1 0.2 0.1 0.3 3.5 0.0 
South Africa Herman 
2009  
2002-
2004 4351 18+ DSM-IV CIDI 8.1 1.4 0.8 4.8 .. 1.9 .. 0.6 
LIFETIME 
PREVALENCE 
              













2016 420 15+ DSM-5 MINI 15.7 .. .. .. .. .. .. 4.5 






6752 18+ DSM-IV CIDI 5.7 0.1 0.2 0.4 0.1 0.3 5.4 0.0 
South Africa Herman 
2009  
2002-
2004 4351 18+ DSM-IV CIDI 15.8 2.7 1.2 9.8 .. 2.8 .. 2.3 
Disorder Abbreviations – AG: Agoraphobia; AN: Anxiety disorders; GA: Generalized anxiety disorder; OC: 








          










2013 603 18+ DSM-IV CIDI .. .. .. .. 9.3 
Burkina Faso Ouedraogo 2019 .. 2587 18+ .. MINI .. .. .. .. .. 
Egypt Ghanem 2009 2003 14640 18-64 .. MINI-Plus 0.19 .. .. .. .. 
Ethiopia Fedaku 2004 1998 1691 16+ ICD-10 CIDI/SCAN .. 0.06 .. .. .. 
Ethiopia Kebede 1999a 1994 1420 15+ ICD-10 CIDI/SRQ .. 0.30 0.40 .. .. 




DSM-IV CIDI//SCAN .. .. .. .. .. 
Kenya Kwobah 2017 2015-2016 420 15+ DSM-5 MINI .. .. .. .. .. 
Mozambique Patel 2007 2014 3892 16-62 DSM-IV PHQ-8 .. .. .. .. .. 
South Africa Rumble 1996 1992 560 15+ .. SRQ PSE-CATEGO .. .. .. 5.0 .. 
LIFETIME 
PREVALENCE       .. .. .. .. .. 










2013 603 18+ DSM-IV CIDI 
.. .. .. .. 30.2 
Burkina Faso Ouedraogo 2019 .. 2587 18+ .. MINI .. .. .. .. 4.1 
Ethiopia Kebede 1999a 1994 1420 15+ ICD-10 CIDI/SRQ .. 0.40 0.50 .. .. 




DSM-IV CIDI//SCAN .. 0.47 .. .. .. 
Kenya Kwobah 2017 2015-2016 420 15+ DSM-5 MINI 1.0 .. .. .. .. 
Mozambique Patel 2007 2014 3892 16-62 DSM-IV PHQ-8 
1.6 / 
4.4 .. .. .. .. 
Disorder Abbreviations – PAR: Paranoid Schizophrenia; PSY: Psychosis/Psychotic disorder; REC: Recurrent 
psychotic syndrome; SCZ: Schizophrenia; SCA: Schizoaffective disorder 
 
 
Table 5. Estimated prevalence of substance use disorders in Africa 
 
POINT 
PREVALENCE            




Criteria Measure HazA HarmA AUD SUD AOD 
Benin Tognon-Techégnonsi 2020 2013 603 18+ DSM-IV CIDI .. .. 4.0 1.3 .. 
Burkina Faso Ouedraogo 2019 .. 2587 18+ .. MINI .. 0.1 1.0 0.5 .. 
Egypt Ghanem 2009 2003 14640 18-64 .. 
MINI-
Plus .. .. 0.03 0.13 .. 
Ethiopia Gedif 2019 2018 1588 18+ .. ASSIST 25.8    .. 
Ghana Thapa 2014 2007-2009 4289 50+ .. NIAAA .. 7.0 .. .. .. 
Morocco Kadri 2010 2004-2005 5498 15+ DSM-IV MINI .. .. 3.4 5.8 .. 
Mozambique Wainberg 2018 2014 3892 16-62 DSM-IV AUDIT 8.0 .. .. .. .. 
Nigeria Adewuya 2018, 2020 2015 11246 18-40 DSM-IV 
MINI-5, 
PHQ-9 .. 8.7 7.1 2.1 .. 
South Africa Thapa 2014 2007-2009 3668 50+ .. NIAAA .. 4.4 .. .. .. 
 Smit 2006 2002 645 15+ DSM-IV AUDIT .. .. 16.7 .. .. 
PERIOD 
PREVALENCE            




Criteria Measure HazA HarmA AUD SUD AOD 
Nigeria Gureje 2006; Kessler 2007, 2009, 2015 2001-2003 
2143-
4985 18+ DSM-IV CIDI .. .. 0.6 0.2 0.8 
South Africa Andersson 2018 2012 977 18-40 DSM-IV 
MINI, 
SSI .. .. 35.5 .. .. 
South Africa 
Herman 2009; Kessler 
2007, 2009, 2015; 
Stein 2008 
2002-2004 4351 18+ DSM-IV CIDI .. .. 5.7 1.5 5.8 
Uganda Nalwadda 2018 2018 351 18+ .. AUDIT 2.9 0.7 0.5 .. .. 
LIFETIME 
PREVALENCE            




Criteria Measure      
Egypt Hamdi 2013 2006 44000 15+ ICD-10 ASI .. .. .. .. 1.6 
Kenya Kwobah 2017 2015-2016 420 15+ DSM-5 MINI .. .. .. .. 11.7 
Kenya Gureje 2006; Kessler 2007, 2009, 2015 2001-2003 
2143-
4985 18+ DSM-IV CIDI .. .. 3.0 1.0 3.7 
South Africa 
Dept. of Health, 
Medical Research 
Council 2007 
2003 10214 15+ .. CAGE .. .. 21M / 7Fa .. .. 
South Africa Herman 2009; Kessler 
2007, 2009, 2015; 
Stein 2008 
2002-2004 4351 18+ DSM-IV CIDI .. .. 14.0 4.5 13.3 
South Africa Parry 1998 1998 13826 15+ .. CAGE .. .. 28M / 10Fa .. .. 
Disorder Abbreviations – AOD: Alcohol or other drug use disorder; AUD: Alcohol use disorder; SUD: Substance 
use disorder; HazA: Hazardous alcohol use; Harm: Harmful/problematic alcohol use 
aStudy only reported gender-stratified estimates (M: Male, F: Female) 
 
